Atopic Dermatitis (Eczema) clinical trials at UC Davis
1 research study open to eligible people
A Study of the Experimental Medicine Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
Sacramento, California and other locations